Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphomaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyBiodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenograftsThe sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activityDiffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Clinical Toxicities of Histone Deacetylase Inhibitors.Vorinostat in solid and hematologic malignanciesPediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.Panobinostat in lymphoid and myeloid malignancies.Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialThe clinical development of histone deacetylase inhibitors as targeted anticancer drugs.The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivoR-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapyTargeting histone deacetyalses in the treatment of B- and T-cell malignancies.Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cellsClassical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation.Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.Novel therapeutics for aggressive non-Hodgkin's lymphoma.Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivoHDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCLMolecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.Clinical efficacy of vorinostat in a patient with leiomyosarcoma.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Histone deacetylase inhibitors: clinical implications for hematological malignancies.miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse modelA phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.The role of angiogenesis in human non-Hodgkin lymphomas.Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomasHistone deacetylase inhibition: an important mechanism in the treatment of lymphoma.Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphomaPhase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
P2860
Q24597424-AF2959A5-C812-497C-9D35-4A8E5C1C5C5AQ26851166-9FE4BB9E-1DCE-4546-A45D-77FB18287122Q27304386-1595BD9B-0EF2-4A08-94B3-286C95296367Q28082536-A5CE0D4D-DCE5-47BB-8010-76D85A1A883DQ28482418-1165ABC0-3734-47AD-8C6A-1066762D9325Q28487756-F5D24236-DC5E-4CEC-ACFE-E03F24560B0CQ30235296-AD8B53F5-A98E-4F8E-AB44-61482E1DE79EQ31135325-D7FAD36D-39FD-4302-A75E-515BBB5B30E3Q33385544-AE12C2D2-7861-4532-A70E-F71A4D31CA82Q33390536-CFDD616A-0B81-49F3-93C2-D9BF7B7E97B0Q33408889-9FDC6B08-DEE0-466D-B494-90F2CA2A7ADDQ33431267-FC3A6E50-F927-4091-BCDB-DA32BF8AEFA4Q33829390-3BE289E5-BFE8-4CBC-817F-92C28C3380E6Q33896749-FC1B4A95-C3F2-4EDF-A3D9-896D631BBB0DQ33934326-5B1A27C8-ACAC-4892-B2C4-289CE730415BQ34360164-C16E218C-A4EE-43F3-A60C-B9CA7E0A3914Q34414452-A5BF8771-E30E-4378-B574-6D62E99180F7Q34416994-B0033646-65A6-47A7-8D3A-B399F6C138A6Q34632964-5D61DC92-E5C5-404F-A3E3-E1F8BD991D29Q35007061-B1B233FA-54ED-41D4-BE5A-C27D787BAD38Q35018530-98111D69-BF67-407D-8B08-BC7E5E0E92A7Q35093521-608F8557-28C5-4DC3-BE25-D770D5A05ED3Q35111768-A1A5E2B0-1D61-445B-879C-66C69B1387FDQ35206717-EACCA9EE-51B4-4FC6-86F0-AF556AD660ECQ35553330-C620059E-BEE6-4CC3-804E-6940DE2351FDQ35691776-48E08B0B-6176-4640-A88C-C75DC3A2D3F6Q35726371-11A34DEF-A549-40EF-A27E-DEF80E9FC094Q35789686-8417694C-93D7-46B4-B519-BACB11AB10D5Q35939690-06209DCC-B199-431D-9AC0-06A0613D2CCCQ36001847-EAAB17CD-574E-4771-B672-7DDB9E53EE7DQ36471327-7F89423D-27D3-4B2F-8BC5-A1196E6C2EA0Q36534059-5C192720-DFC8-4575-BF71-BD167B3A1C5DQ36670881-7E54C1CB-8634-4564-9E69-9A1EE7438547Q36703448-9B201B36-EA2D-4D6E-B00E-126AF4BC4350Q36814349-5B8D9D9A-C556-4C26-B7CD-8FC52917B041Q37117964-08025472-7EA1-48AF-B9BF-56225E78E55FQ37150016-3460CB2C-A730-4CB5-BEB7-C98475BC6B07Q37200384-EE1729AC-ECF6-49E9-9E61-D4D0FD6E8225Q37321798-318CA16C-D2E1-4372-BF22-FB8F62691531Q37379984-99A41AEF-9FF5-4C0C-B1D9-EA3F6D46D9EC
P2860
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Phase II trial of oral vorinos ...... diffuse large-B-cell lymphoma.
@ast
Phase II trial of oral vorinos ...... diffuse large-B-cell lymphoma.
@en
type
label
Phase II trial of oral vorinos ...... diffuse large-B-cell lymphoma.
@ast
Phase II trial of oral vorinos ...... diffuse large-B-cell lymphoma.
@en
prefLabel
Phase II trial of oral vorinos ...... diffuse large-B-cell lymphoma.
@ast
Phase II trial of oral vorinos ...... diffuse large-B-cell lymphoma.
@en
P2093
P356
P1433
P1476
Phase II trial of oral vorinos ...... diffuse large-B-cell lymphoma.
@en
P2093
B Coiffier
B D Cheson
E D Jacobsen
J L Ricker
S R Frankel
S S Randolph
P304
P356
10.1093/ANNONC/MDN031
P577
2008-02-21T00:00:00Z